Evaluation of Cardiac Sympathetic Nerve Activity and Aldosterone Suppression in Patients With Decompensated Acute Heart Failure on the Treatment Containing Intravenous Atrial Natriuretic Peptide

Evaluation of Cardiac Sympathetic Nerve Activity and Aldosterone Suppression in Patients With Decompensated Acute Heart Failure on the Treatment Containing Intravenous Atrial Natriuretic Peptide - ANP in Decompensated AHF

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009170

Enrollment

200

Registered

2012-10-23

Start date

2004-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated acute heart failure

Interventions

intravenous atrial natriuretic peptide (ANP)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Admitted to our institutions 2) A first episode of decompensated AHF 3) Left ventricular (LV) ejection fraction (EF) of <45%.

Exclusion criteria

Exclusion criteria: 1) Cardiogenic shock or hypotension 2) History of myocardial infarction or coronary artery disease 3) Severe heart failure requiring mechanical support (intraaortic balloon pumping, left ventricular assist device, or cardiac resynchronization therapy) 4) Requiring heart transplantation

Design outcomes

Primary

Measure	Time frame
I-123 MIBG scintigraphic parameters plasma aldosterone concentrations	—

Secondary

Measure	Time frame
Left ventricular (LV) end-diastolic volume, end-systolic volume, and ejection fraction plasma BNP concentrations	—

Countries

Japan

Contacts

Public ContactShu Kasama

Kitakanto Cardiovascular Hospital Internal Medicine

s-kasama@bay.wind.ne.jp027-232-7111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026